CIAM
AKBA icon

Caitong International Asset Management’s Akebia Therapeutics AKBA Stock Holding History

Caitong International Asset Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$144K Buy
103,652
+83,030
+403% +$114K 0.03% 467
2025
Q4 		$33.2K Buy
20,622
+18,037
+698% +$37.8K 0.01% 855
2025
Q3 		$7.06K Buy
2,585
+2,336
+938% +$7.77K ﹤0.01% 1126
2025
Q2 		$906 Buy
+249
New +$684 ﹤0.01% 1590

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Caitong International Asset Management's AKBA Position: Q1 2026 in Review

Caitong International Asset Management increased its Akebia Therapeutics (AKBA) stake by 403% in Q1 2026, buying an estimated $114K and bringing the position to 103,652 shares worth $144K. The position accounts for 0.03% of the portfolio, ranked #467.

Caitong International Asset Management first reported a position in AKBA in Q2 2025 and has held it in 4 quarters since. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Caitong International Asset Management held 103,652 shares of Akebia Therapeutics worth $144K as of Q1 2026.
  • Caitong International Asset Management bought 83,030 Akebia Therapeutics shares in Q1 2026, an estimated $114K.
  • Akebia Therapeutics made up 0.03% of Caitong International Asset Management's portfolio in Q1 2026, its #467 holding.
  • Caitong International Asset Management first reported a position in Akebia Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.